UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2327-2333

2012

Volltextzugriff (PDF)

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

Journal of clinical oncology, 2011-03, Vol.29 (7), p.934-943

2011

Volltextzugriff (PDF)

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8664-8670

2005

Volltextzugriff (PDF)

Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2336-2341

2008

Volltextzugriff (PDF)

Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4922-4927

2006

Volltextzugriff (PDF)

Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database

Journal of clinical oncology, 2013-10, Vol.31 (29), p.3656-3663

2013

Volltextzugriff (PDF)

Impact of hospital volume on recurrence and survival after surgery for gastric cancer

Annals of surgery, 2007-03, Vol.245 (3), p.426-434

2007

Volltextzugriff (PDF)

Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

Journal of thoracic oncology, 2012-05, Vol.7 (5), p.906-912

2012

Volltextzugriff (PDF)

Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144

Journal of clinical oncology, 2006-08, Vol.24 (22), p.3542-3547

2006

Volltextzugriff (PDF)

Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1819-1825

2005

Volltextzugriff (PDF)

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Cancer, 2014-10, Vol.120 (19), p.2980-2985

2014

Volltextzugriff (PDF)

Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials

JNCI : Journal of the National Cancer Institute, 2011-10, Vol.103 (20), p.1498-1506

2011

Volltextzugriff (PDF)

Polymorphisms in folate‐metabolizing enzymes and response to 5‐fluorouracil among patients with stage II or III rectal cancer (INT‐0144; SWOG 9304)

Cancer, 2014-11, Vol.120 (21), p.3329-3337

2014

Volltextzugriff (PDF)

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation

Clinical cancer research, 2015-04, Vol.21 (7), p.1583-1590

2015

Volltextzugriff (PDF)

Don Quixote and the quest for personalized medicine

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2619-2620

2008

Volltextzugriff (PDF)

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

Clinical trials (London, England), 2011-10, Vol.8 (5), p.591-600

2011

Volltextzugriff (PDF)

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study

Investigational new drugs, 2004-01, Vol.22 (1), p.91-97

2004

Volltextzugriff (PDF)

Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus

The American journal of medicine, 1995-03, Vol.98 (3), p.237-242

1995

Volltextzugriff (PDF)

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time

Annals of internal medicine, 1999-07, Vol.131 (1), p.14

1999

Volltextzugriff (PDF)

SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS4145-TPS4145

2013

Volltextzugriff (PDF)

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study

Investigational new drugs, 2004-11, Vol.22 (4), p.467-473

2004

Volltextzugriff (PDF)

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study

Investigational new drugs, 2004-08, Vol.22 (3), p.335-341

2004

Volltextzugriff (PDF)

Assessment of Infusional 5-Fluorouracil Schedule and Dose Intensity: A Southwest Oncology Group and Eastern Cooperative Oncology Group Study

Clinical colorectal cancer, 2005-07, Vol.5 (2), p.119-123

2005

Volltextzugriff (PDF)

Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304)

Cancer, 2014-07, Vol.120 (21), p.3329-3337

2014

Volltextzugriff (PDF)

Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4019-4019

2012

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Humans
(43)
Life Sciences & Biomedicine
(42)
Female
(36)
Male
(33)
Adult
(27)
Middle Aged
(27)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Oncology
(23)
Aged
(22)
Tumors
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Treatment Outcome
(12)
Fluorouracil - Administration & Dosage
(11)
Disease-Free Survival
(10)
Gastroenterology. Liver. Pancreas. Abdomen
(10)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(10)
Aged, 80 And Over
(8)
Chemotherapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set

Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127

Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database

Impact of hospital volume on recurrence and survival after surgery for gastric cancer

Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)

Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144

Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer

Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials

Polymorphisms in folate‐metabolizing enzymes and response to 5‐fluorouracil among patients with stage II or III rectal cancer (INT‐0144; SWOG 9304)

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation

Don Quixote and the quest for personalized medicine

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study

Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time

SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study

Assessment of Infusional 5-Fluorouracil Schedule and Dose Intensity: A Southwest Oncology Group and Eastern Cooperative Oncology Group Study

Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304)

Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727)

Suchergebnisse filtern